Carlsmed, Inc. (CARL)
| Market Cap | 477.38M +51.7% |
| Revenue (ttm) | 71.78M +60.4% |
| Net Income | -40.06M |
| EPS | -1.48 |
| Shares Out | 27.40M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 261,682 |
| Open | 17.30 |
| Previous Close | 17.22 |
| Day's Range | 16.91 - 18.25 |
| 52-Week Range | 8.50 - 19.15 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 22.00 (+26.29%) |
| Earnings Date | Nov 10, 2026 |
About CARL
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The company was incorporated in 2018 and is based in Carlsbad, California.
Financial Performance
In 2025, Carlsmed's revenue was $50.51 million, an increase of 85.94% compared to the previous year's $27.17 million. Losses were -$30.22 million, 21.6% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for CARL stock is "Strong Buy." The 12-month stock price target is $22.0, which is an increase of 26.29% from the latest price.
News
Carlsmed to Participate in Upcoming Investor Conferences
CARLSBAD, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions...
Carlsmed price target raised to $23 from $20 at Truist
Truist raised the firm’s price target on Carlsmed (CARL) to $23 from $20 and keeps a Buy rating on the shares. The company’s Q3 revenue and EBITDA topped expectations, with…
Carlsmed price target raised to $26 from $24 at BTIG
BTIG raised the firm’s price target on Carlsmed (CARL) to $26 from $24 and keeps a Buy rating on the shares. The company reported strong surgeon adds and growing utilization,…
Carlsmed Earnings Call Transcript: Q3 2026
Q3 revenue grew 65% YoY to $21.6M, with 76% procedure-volume growth and positive operating leverage. FY 2026 revenue guidance rose to $78M–$80M, supported by reimbursement changes and expanding lumbar and cervical offerings.
Carlsmed Earnings release: Q3 2026
Carlsmed released its Q3 2026 earnings on November 10, 2026, summarizing the period's financial results.
Carlsmed Quarterly report: Q3 2026
Carlsmed has published its Q3 2026 quarterly earnings report on November 10, 2026.
Carlsmed reports Q3 EPS (34c), consensus (38c)
Reports Q3 revenue $16.67M, consensus $19.16M. “The third quarter represented strong execution against our long-term strategy as we delivered 65% revenue growth and advanced our leadership position in...
Carlsmed raises FY26 revenue view to $78M-$80M from $74M-$78M
Consensus $76.71M. The company said, “Revenue for the full year 2026 is expected to be in the range of $78 million to $80 million, representing growth of over 56% at…
Carlsmed® Reports Third Quarter 2026 Financial Results and Raises Full-Year Guidance
Third quarter 2026 revenue of $21.6 million, representing 65% growth year-over-year Full year 2026 revenue guidance raised to $78 million to $80 million CARLSBAD, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE...
Carlsmed Slides: Corporate presentation
Carlsmed has posted slides in relation to its latest quarterly earnings report, which was published on November 10, 2026.
Carlsmed, Inc. to Report Third Quarter 2026 Financial Results on November 10, 2026
CARLSBAD, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions...
Carlsmed launches aprevo Lumbar Bi-lateral Posterior System in the U.S.
Carlsmed (CARL) announced the U.S. commercial launch of its aprevo Lumbar Bi-lateral Posterior System at the North American Spine Society’s 41st Annual Meeting, or NASS, in San Antonio, Texas. The…
Carlsmed Launches aprevo® Lumbar Bi-lateral Posterior System
CARLSBAD, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the U.S. commercial launch of its aprevo® Lumbar Bi-lateral Posterior S...
Carlsmed price target raised to $24 from $23 at BTIG
BTIG raised the firm’s price target on Carlsmed (CARL) to $24 from $23 and keeps a Buy rating on the shares as part of a broader research note previewing Q3…
Carlsmed, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CARLSBAD, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions...
Carlsmed appoints Jarc as Chief Product, AI Officer
Carlsmed (CARL) announced that Tony Jarc, Ph.D. has been appointed to the newly-created position of Chief Product and AI Officer, effective immediately. Dr. Jarc will lead the development and commerci...
Carlsmed Appoints Tony Jarc as Chief Product and AI Officer
CARLSBAD, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions...
Carlsmed appoints Heppenstall as Chief Financial Officer
Carlsmed (CARL) announced that Richard Heppenstall has been appointed Chief Financial Officer, effective immediately. Heppenstall succeeds Leo Greenstein, who has served as CFO since 2023 and will be ...
Carlsmed Appoints Richard Heppenstall as Chief Financial Officer
CARLSBAD, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solution...
Carlsmed files patent infringement lawsuit against DeGen Medical
Carlsmed (CARL) filed a patent infringement lawsuit against DeGen Medical in the United States District Court for the District of South Carolina Florence Division. The complaint asserts that DeGen is…
Carlsmed, Inc. Files Patent Infringement Lawsuit against DeGen Medical
CARLSBAD, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today filed a...
Carlsmed promotes Jeff Bertolini to COO role
Carlsmed (CARL) announced that Jeff Bertolini has been promoted to the role of COO, effective immediately. Jeff joined Carlsmed in September 2024, most recently serving as the company’s senior VP,…
Carlsmed, Inc. Announces Chief Operating Officer Appointment
CARLSBAD, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solution...
Carlsmed files $250M mixed securities shelf
16:16 EDT Carlsmed (CARL) files $250M mixed securities shelf
Carlsmed Registration statement: Registration filing
Carlsmed filed a registration statement on August 14, 2026, providing details about a securities offering with the SEC.